Myeloproliferative neoplasm causes: Difference between revisions
Shyam Patel (talk | contribs) No edit summary |
Shyam Patel (talk | contribs) (→Causes) |
||
| Line 15: | Line 15: | ||
Polycythemia vera | Polycythemia vera | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*''JAK2'' ''V617F'' in 95% of cases | *''JAK2'' ''V617F'' in 95% of cases<ref name="pmid25832853">{{cite journal| author=Griesshammer M, Gisslinger H, Mesa R| title=Current and future treatment options for polycythemia vera. | journal=Ann Hematol | year= 2015 | volume= 94 | issue= 6 | pages= 901-10 | pmid=25832853 | doi=10.1007/s00277-015-2357-4 | pmc=4420843 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25832853 }} </ref> | ||
*''CALR'' | *''CALR'' | ||
*''MPL'' | *''MPL'' | ||
Revision as of 22:22, 12 July 2018
|
Myeloproliferative Neoplasm Microchapters |
|
Differentiating myeloproliferative neoplasm from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Myeloproliferative neoplasm causes On the Web |
|
American Roentgen Ray Society Images of Myeloproliferative neoplasm causes |
|
Directions to Hospitals Treating Myeloproliferative neoplasm |
|
Risk calculators and risk factors for Myeloproliferative neoplasm causes |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2] Shyam Patel [3]
Overview
Myeloproliferative neoplasm is caused by mutations in various genes. Different gene mutations are responsible for each of the 8 subtypes of myeloproliferative neoplasms.[1]
Causes
| Myeloproliferative neoplasm subtype | Causative gene mutation |
|---|---|
|
Polycythemia vera |
|
|
Essential thrombocythemia |
|
|
Primary myelofibrosis |
|
|
Chronic myeloid leukemia |
|
|
Chronic neutrophilic leukemia |
|
|
Chronic eosinophilic leukemia |
|
|
Myeloproliferative neoplasm, unclassifiable |
|
|
Mastocytosis |
|
References
- ↑ Ganfyd. Polycythaemia vera 2015.http://www.ganfyd.org/index.php?title=Polycythemia_vera
- ↑ Griesshammer M, Gisslinger H, Mesa R (2015). "Current and future treatment options for polycythemia vera". Ann Hematol. 94 (6): 901–10. doi:10.1007/s00277-015-2357-4. PMC 4420843. PMID 25832853.
- ↑ Antonioli E, Carobbio A, Pieri L, Pancrazzi A, Guglielmelli P, Delaini F; et al. (2010). "Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia". Haematologica. 95 (8): 1435–8. doi:10.3324/haematol.2009.021444. PMC 2913097. PMID 20418246.
- ↑ Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martínez-Trillos A, Casetti I; et al. (2014). "Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis". Blood. 124 (7): 1062–9. doi:10.1182/blood-2014-05-578435. PMC 4133481. PMID 24986690.
- ↑ Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A; et al. (2013). "Recurrent SETBP1 mutations in atypical chronic myeloid leukemia". Nat Genet. 45 (1): 18–24. doi:10.1038/ng.2495. PMC 3588142. PMID 23222956.
- ↑ Szuber N, Tefferi A (2018). "Chronic neutrophilic leukemia: new science and new diagnostic criteria". Blood Cancer J. 8 (2): 19. doi:10.1038/s41408-018-0049-8. PMC 5811432. PMID 29440636.
- ↑ 7.0 7.1 7.2 Falchi L, Verstovsek S (2015). "Eosinophilia in Hematologic Disorders". Immunol Allergy Clin North Am. 35 (3): 439–52. doi:10.1016/j.iac.2015.04.004. PMC 4515577. PMID 26209894.